Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers

被引:111
作者
Warren, DS
Zachary, AA
Sonnenday, CJ
King, KE
Cooper, M
Ratner, LE
Shirey, RS
Haas, M
Leffell, MS
Montgornery, RA [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA
关键词
ABO incompatible; IVIG; plasmapheresis; positive crossmatch;
D O I
10.1111/j.1600-6143.2004.00364.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
ABO incompatibility and human leukocyte antigen (HLA) sensitization remain the two largest barriers to optimal utilization of kidneys from live donors. Here we describe the first successful transplantation of patients who were both ABO incompatible and crossmatch positive with their only available donor. A preconditioning regimen of plasmapheresis (PP) and low-dose CMV hyperimmune globulin (CMVIg) was delivered every other day until donor-specific antibody (DSA) titers were reduced to a safe level and isoagglutinin titers were less than or equal to16. Each patient received quadruple sequential immunosuppression, splenectomy and three protocol post-transplant PP/CMVIg treatments. There was no hyperacute rejection. Two of the three patients had a persistent positive cytotoxic crossmatch on the day of transplant and eliminated their DSA subsequently. Antibody-mediated rejection (AMR) in one patient was reversed by reinitiating PP/CMVIg and anti-CD20. The patients are more than 9 months post-transplant with excellent graft function. Preconditioning with PP/CMVIg results in a durable suppression of DSA and permits accommodation of the allograft to a discordant blood type. The ability to cross these two barriers simultaneously is clinically important as sensitized patients have often exhausted their blood type compatible living donors during previous transplants.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 30 条
[1]  
ALEXANDRE GPJ, 1985, TRANSPLANT P, V17, P138
[2]  
ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538
[3]   Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes [J].
Baldwin, WM ;
Samaniego-Picota, M ;
Kasper, EK ;
Clark, AM ;
Czader, M ;
Rohde, C ;
Zachary, AA ;
Sanfilippo, F ;
Hruban, RH .
TRANSPLANTATION, 1999, 68 (06) :894-900
[4]  
BRECHER ME, 2002, TECHNICAL MANUAL
[5]  
BREIMER ME, 1986, TRANSPLANTATION, V42, P88
[6]   REPETITIVE-A EPITOPE (TYPE-3 CHAIN-A) DEFINED BY BLOOD GROUP-A1-SPECIFIC MONOCLONAL-ANTIBODY TH-1 - CHEMICAL BASIS OF QUALITATIVE-A1 AND A2-DISTINCTION [J].
CLAUSEN, H ;
LEVERY, SB ;
NUDELMAN, E ;
TSUCHIYA, S ;
HAKOMORI, SI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (04) :1199-1203
[7]   QUANTITATIVE MEASURMENTS CONCERNING A AND B ANTIGEN SITES [J].
ECONOMID.J ;
HUGHESJO.NC ;
GARDNER, B .
VOX SANGUINIS, 1967, 12 (05) :321-&
[8]   ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. [J].
Gloor, JM ;
Lager, DJ ;
Moore, SB ;
Pineda, AA ;
Fidler, ME ;
Larson, TS ;
Grande, JP ;
Schwab, TR ;
Griffin, MD ;
Prieto, M ;
Nyberg, SL ;
Velosa, JA ;
Textor, SC ;
Platt, JL ;
Stegall, MD .
TRANSPLANTATION, 2003, 75 (07) :971-977
[9]   SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIG) - A POTENTIAL TOOL FOR TRANSPLANTATION OF IMMUNIZED PATIENTS [J].
GLOTZ, D ;
HAYMANN, JP ;
SANSONETTI, N ;
FRANCOIS, A ;
MENOYOCALONGE, V ;
BARIETY, J ;
DRUET, P .
TRANSPLANTATION, 1993, 56 (02) :335-337
[10]   THE SIGNIFICANCE OF THE ANTI-CLASS-I ANTIBODY-RESPONSE .1. CLINICAL AND PATHOLOGICAL FEATURES OF ANTI-CLASS I-MEDIATED REJECTION [J].
HALLORAN, PF ;
WADGYMAR, A ;
RITCHIE, S ;
FALK, J ;
SOLEZ, K ;
SRINIVASA, NS .
TRANSPLANTATION, 1990, 49 (01) :85-91